Form 4: Aclaris Therapeutics Executive Neal Walker Reports Stock Transactions

Neal Walker, Interim President and CEO of Aclaris Therapeutics, reports the acquisition and disposal of common stock and restricted stock units.

Summary

• On June 1, 2024, Neal Walker, Interim President and CEO of Aclaris Therapeutics, executed transactions involving Aclaris Therapeutics common stock and restricted stock units.
• Walker acquired 9,466 shares of common stock through the vesting of restricted stock units.
• Simultaneously, 2,722 shares were disposed of to cover tax withholding obligations at a price of $1.03 per share.
• Following these transactions, Walker directly owns 1,299,115 shares of Aclaris Therapeutics common stock and 104,134 restricted stock units.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions, which carries a neutral sentiment.

Industry Context

This filing is a routine disclosure of stock transactions by a company executive, which is common in the pharmaceutical industry. It provides transparency into the executive's holdings and transactions in the company's stock.

Comparison to Industry Standards

• Executive stock transactions are a common occurrence in publicly traded companies, particularly in the pharmaceutical sector.
• Form 4 filings are standard practice and are comparable across companies like Pfizer, Amgen, and Johnson & Johnson, where executives routinely report similar transactions.
• The size and frequency of these transactions are typical for executives receiving stock-based compensation.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in the executive's holdings.
• Employees may be indirectly affected by the executive's actions, but the impact is likely minimal.

Key Dates